ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors

-- Bristol Myers Squibb exercises an exclusive license option for ArsenalBio's AB-4000 series programs -- -- ArsenalBio is eligible for additional milestone payments and royalties as the programs advance -- SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T cell therapies for solid tumors, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its exclusive ...